Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP process

This article was originally published in The Tan Sheet

Executive Summary

Parties involved in ERSP cases have the opportunity to participate in the review process under specific circumstances, counter to comments included in an article in the Oct. 16 issue of "The Tan Sheet" (1"The Tan Sheet" Oct. 16, 2006, p. 13). "Under ERSP's policies and procedures, the person or legal entity that initiates the inquiry has the option of actively participating in the review process, but is not required to do so," ERSP Director Peter Marinello tells "The Tan Sheet." When parties involved in cases choose to participate, they have access to all non-confidential submissions and can contribute comments to the record, Marinello says. However, "parties that elect to remain anonymous may not review the submissions or contribute to the case record," he adds...

You may also be interested in...



Demand Letters, NAD Review Can Check Firms’ Claims Without Court – Lawyer

Dietary supplement and nutritional product firms challenging competitors' claims have several options more cost-effective than litigation, advises Ivan Wasserman, a partner at Kelly Drye Collier Shannon (Washington, D.C.)

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

AstraZeneca Vaccine May Only Gain EU Approval In Under 70s

AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel